Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;21(10):1105-1124.
doi: 10.1080/14737140.2021.1944109. Epub 2021 Sep 1.

The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

Komal Jhaveri  1   2 , Howard A Burris Rd  3 , Timothy A Yap  4 , Erika Hamilton  3 , Hope S Rugo  5 , Jonathan W Goldman  6 , Stephen Dann  7 , Feng Liu  7 , Gilbert Y Wong  7 , Heike Krupka  7 , Geoffrey I Shapiro  8
Affiliations
Review

The evolution of cyclin dependent kinase inhibitors in the treatment of cancer

Komal Jhaveri et al. Expert Rev Anticancer Ther. 2021 Oct.

Abstract

Introduction: The cell cycle cyclin-dependent kinases (CDKs) play a critical role in controlling the transition between cell cycle phases, as well as cellular transcription. Aberrant CDK activation is common in cancer, and deregulation of the cell cycle a key hallmark of cancer. Although CDK4/6 inhibitors are now a standard-of-care option for first- and second-line HR+/HER2- metastatic breast cancer, resistance inevitably limits their clinical benefit.Areas covered: Early pan-CDK inhibitors targeted the cell cycle and RNA polymerase II phosphorylation, but were complicated by toxicity, providing a rationale and need for the development of selective CDK inhibitors. In this review, we highlight selected recent literature to provide a narrative review summarizing the current CDK inhibitor therapeutic landscape. We detail the challenges associated with targeting CDKs for the treatment of breast and other cancers and review emerging biomarkers that may aid response prediction. We also discuss the risk-benefit ratio for CDK therapy and explore promising combination approaches.Expert opinion: Although CDK inhibitors may stem the proliferation of cancer cells, resistance remains an issue, and currently there are limited biomarkers to predict response to therapy. Ongoing research investigating CDK inhibitors in cancer is of paramount importance to define appropriate and effective treatment regimens.

Keywords: Breast; biomarkers; cancer; cell cycle; cyclin dependent kinase inhibitor; oncology; resistance.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

K Jhaveri has served as a consultant and on the advisory boards for Novartis, Spectrum Pharmaceuticals, ADC Therapeutics, Pfizer, BMS, Jounce Therapeutics, Taiho Oncology, Genentech, Synthon, AbbVie, AstraZeneca, Lilly Pharmaceuticals, Intellisphere, Seattle Genetics, Blueprint Medicines; research funding from Novartis, Clovis Oncology, Genentech, AstraZeneca, ADC Therapeutics, Novita Pharmaceuticals, Debio Pharmaceuticals, Pfizer, Lilly Pharmaceuticals, Zymeworks, Immunomedics, Puma Biotechnology.

HA Burris 3rd has received consulting fees paid to institution from AstraZeneca, FORMA Therapeutics, Celgene, Incyte, research funding paid to institution: Roche/Genentech, Bristol-Myers Squibb, Incyte, AstraZeneca, MedImmune, Macrogenics, Novartis, Boehringer Ingelheim, Lilly, Seattle Genetics, Merck, Agios, Jounce Therapeutics, Moderna Therapeutics, CytomX Therapeutics, GlaxoSmithKline, Verastem, Tesaro, BioMed Valley Discoveries, TG Therapeutics, Vertex, eFFECTOR Therapeutics, Janssen, Gilead Sciences, BioAtla, CicloMed, Harpoon Therapeutics, Arch, Arvinas, Revolution Medicines, Array BioPharma, Bayer, BIND Therapeutics, Kyocera, miRNA Therapeutics, Pfizer, Takeda/Millenium, Foundation Medicine, Expert Testimony for Novartis.

TA Yap has received research support from AstraZeneca, Bayer, Pfizer, Tesaro, Jounce, Lilly, Seattle Genetics, Kyowa, Constellation, and Vertex Pharmaceuticals; consultancies from Aduro, Almac, AstraZeneca, Atrin, Bayer, Bristol-Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, Ignyta, Jansen, Merck, Pfizer, Roche, Seattle Genetics, and Vertex Pharmaceuticals.

E Hamilton has received consulting fees paid to institution only (no personal fees) from Pfizer, Genentech/Roche, Eli Lilly and Company (Lilly), Puma Biotechnology, Daiichi Sankyo, Mersana Therapeutics, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, and Black Diamond; and research/clinical trial support paid to institution only (no personal fees) from AstraZeneca, Hutchinson MediPharma, OncoMed, MedImmune, StemCentrx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millenium, TapImmune, Cascadian, Lilly, BerGenBio, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, Macrogenics, AbbVie, Immunomedics, FujiFilm, Effector, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceutical, EMD Serono, Daiichi Sankyo, ArQule, Syros, Clovis, Cytomx, InventisBio, Deciphera, Unum Therapeutics, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, and Silverback Therapeutics.

HS Rugo has received research support to the University of California San Francisco from Eisai, Genentech, Lilly, MacroGenics, Merck, Novartis, OBI Pharma, Odonate Therapeutics, Immunomedics, Daiichi-Sankyo, Daichi, Sermonix, and Pfizer; has served in a consulting role with Samsung and Puma; and has received travel support from Pfizer, Novartis, AstraZeneca, and Roche.

JW Goldman has received research grants from Pfizer and Lilly, and consultant fees from Pfizer.

S Dann is an employee of Pfizer and holds stock in Pfizer.

F Liu is an employee of Pfizer and holds stock in Pfizer.

GY Wong is a former employee of Pfizer and holds stock in Pfizer; is employee of BeiGene and holds stock in BeiGene.

H Krupka is a former employee of Pfizer and holds stock in Pfizer.

GI Shapiro has received research funding from Lilly, Merck KGaA/EMD-Serono, Merck, and Sierra Oncology; served on advisory boards for Pfizer, Lilly, G1 Therapeutics, Roche, Merck KGaA/EMD-Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin, and Concarlo Holdings; and holds a patent for ‘Dosage Regimen for Sapacitabine and Seliciclib,’ also issued to Cyclacel Pharmaceuticals, and a pending patent, ‘Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition,’ together with Liam Cornell.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Figures

Figure 1.
Figure 1.
CDK4/6 inhibition in the cell cycle.
Figure 2.
Figure 2.
Genes commonly perturbed in cancer (a); Cancer types and alteration frequency (b); Poorer overall survival associated with gene alterations (c).
Figure 3.
Figure 3.
Possible mechanisms of resistance to CDK4/6 inhibitors.
See this image and copyright information in PMC

References

    1. Woo RA, Poon RY. Cyclin-dependent kinases and S phase control in mammalian cells. Cell Cycle. 2003;2(4):316–324. - PubMed
    1. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005;30(11):630–641. - PubMed
    1. Cerqueira A, Martín A, Symonds CE, et al. Genetic characterization of the role of the Cip/Kip family of proteins as cyclin-dependent kinase inhibitors and assembly factors. Mol Cell Biol 2014;34 (8):1452–1459. - PMC - PubMed
    1. Cobrinik D Pocket proteins and cell cycle control. Oncogene. 2005;24(17):2796–2809. - PubMed

    1. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671–682.

      • This paper discusses that RB, the retinoblastoma protein, has been identified as a crucial tumor suppressor. It further describes the distinct cellular functions of RB that play a role in preventing tumor initiation versus its role in preventing tumor progression in distinct cell types.

Publication types

Substances